Evidence map›Paper›PMID 35250985›Full record

ArticleFrontiers in immunology2022

A Simplified SARS-CoV-2 Mouse Model Demonstrates Protection by an Oral Replicon-Based mRNA Vaccine.

Vijayakumar Jawalagatti, Perumalraja Kirthika, Chamith Hewawaduge, Ji-Young Park, Myeon-Sik Yang, Byungkwan Oh, Mi Young So, Bumseok Kim, John Hwa Lee

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Live-AttenuatedVaccines · 2023
    Article
  4. Animal models for COVID-19: advances, gaps and perspectives.Signal transduction and targeted therapy · 2022
    Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Vijayakumar JawalagattiDepartment of Veterinary Public Health, College of Veterinary Medicine, Jeonbuk National University, Iksan, South Korea.
Perumalraja KirthikaDepartment of Veterinary Public Health, College of Veterinary Medicine, Jeonbuk National University, Iksan, South Korea.
Chamith HewawadugeDepartment of Veterinary Public Health, College of Veterinary Medicine, Jeonbuk National University, Iksan, South Korea.
Ji-Young ParkDepartment of Veterinary Public Health, College of Veterinary Medicine, Jeonbuk National University, Iksan, South Korea.
Myeon-Sik YangDepartment of Veterinary Pathology, College of Veterinary Medicine, Jeonbuk National University, Iksan, South Korea.
Byungkwan OhDepartment of Veterinary Pathology, College of Veterinary Medicine, Jeonbuk National University, Iksan, South Korea.
Mi Young SoDepartment of Veterinary Pathology, College of Veterinary Medicine, Jeonbuk National University, Iksan, South Korea.
Bumseok KimDepartment of Veterinary Pathology, College of Veterinary Medicine, Jeonbuk National University, Iksan, South Korea.
John Hwa LeeDepartment of Veterinary Public Health, College of Veterinary Medicine, Jeonbuk National University, Iksan, South Korea.
Jeonbuk National University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A mouse model of SARS-CoV-2 that can be developed in any molecular biology lab with standard facilities will be valuable in evaluating drugs and vaccines. Here we present a simplified SARS-CoV-2 mouse model exploiting the rapid adenoviral purification method. Mice that are sensitive to SARS-CoV-2 infection were generated by transducing human angiotensin-converting enzyme 2 (hACE2) by an adenovirus. The expression kinetics of the hACE2 in transduced mice were assessed by immunohistochemistry, RT-PCR, and qPCR. Further, the ability of the hACE2 to support viral replication was determined

Indexed as

AnimalsAntibodies, NeutralizingCell LineCOVID-19COVID-19 VaccinesDisease Models, AnimalHEK293 CellsHumansLungMaleMiceMice, Inbred BALB CmRNA VaccinesRepliconSARS-CoV-2Spike Glycoprotein, CoronavirusAntibodies, NeutralizingCOVID-19 VaccinesmRNA VaccinesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Vaccines, Syntheticmouse modelmRNAoralSARS-CoV-2vaccine

Identifiers

PMID35250985
PMCPMC8888445
OpenAlexW4213245029

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.